Back to News
Market Impact: 0.3
Zealand Pharma's ZP9830 Shows Favorable Tolerability In Phase 1 Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Zealand Pharma reported positive topline results from the multiple ascending dose portion of its Phase 1 trial of ZP9830, an investigational Kv1.3 ion channel blocker being developed for autoimmune and inflammatory diseases. The brief report provides no efficacy or safety figures, and the results are from an early-stage trial.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ZEAL0.75
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Elice shares plunge 28% on debut as investor doubts over AI trade deepen
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- What Neoclouds Like CoreWeave Reveal About the Fragile AI Economy: Big Take Podc
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Earnings-Triggered Research Automations: A Control Guide